Teriparatide acetate
- CAS No.
- 52232-67-4
- Chemical Name:
- Teriparatide acetate
- Synonyms
- Parathar;hPTH (1-34);Teriparatid;Teroparatide;CNV-38d(1-34);Teriparatide CRS;PTH (HUMAN, 1-34);Teriparatida(net);PTH (1-34) (HUMAN);Parathormone (1-34)
- CBNumber:
- CB2284468
- Molecular Formula:
- C172H278N52O47S2
- Molecular Weight:
- 3890.49792
- MOL File:
- 52232-67-4.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/7/9 21:58:15
| Melting point | >205oC (dec.) |
|---|---|
| RTECS | SQ7770000 |
| storage temp. | −20°C |
| solubility | DMSO (Slightly), Water (Slightly) |
| form | powder |
| color | White to Off-White |
| Water Solubility | Soluble to 0.40 mg/ml in water |
| Sequence | H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH |
| Stability | Hygroscopic |
| CAS DataBase Reference | 52232-67-4(CAS DataBase Reference) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H302-H227 |
| Precautionary statements | P210-P264-P270-P280-P301+P312-P330-P370+P378-P403+P235-P501 |
| WGK Germany | 3 |
| HS Code | 2937190000 |
Teriparatide acetate price More Price(4)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | P3796 | Parathyroid Hormone Fragment 1-34 human ≥95% (HPLC), powder | 52232-67-4 | 0.1MG | ₹15274.08 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | P3796 | Parathyroid Hormone Fragment 1-34 human ≥95% (HPLC), powder | 52232-67-4 | 0.5MG | ₹23879.95 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | P3796 | Parathyroid Hormone Fragment 1-34 human ≥95% (HPLC), powder | 52232-67-4 | 1MG | ₹42975.25 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | 05-23-5501 | Parathyroid Hormone 1-34, Human - CAS 52232-67-4 - Calbiochem N-terminal active peptide fragment of the native hormone that functions as a regulatory factor in the homeostatic control of Ca2+ and phosphate metabo | 52232-67-4 | 1MG | ₹22380 | 2022-06-14 | Buy |
Teriparatide acetate Chemical Properties,Uses,Production
Description
The anabolic drug teriparatide acetate (TA), known as recombinant human parathyroid hormone 1–34, which directly promotes bone formation by generating new osteocytes, has been introduced as a novel therapeutic agent for osteoporosis. Distinct from antiresorptive drug treatment, patients with osteonecrosis of the jaw showed successful clinical outcomes after weekly administration of TA. In addition, adverse outcomes of long-term bisphosphonate treatment, such as bone fracture, were healed after usage of TA, and better bone mass and mineral density improvements at the lumbar spine and femoral neck were achieved with TA treatment than with bisphosphonate treatment[1].
Uses
A fragment of human parathyroid hormone (hPTH) peptide sequence containing the 34 N-terminal residues of hPTH. This fragment was also found to be an agonist at PTH1 and PTH2 receptors.
General Description
Teriparatide is a recombinantform of parathyroid hormone, which is used for the treatmentof osteoporosis in men and postmenopausal women.The N-terminal region possesses 34 amino acids, which areidentical to the biologically active region of the 84-aminoacid sequence of human parathyroid hormone. It has beenshown to act on osteoblasts to stimulate new bone growthand improve bone density.
Pharmacokinetics
If administered once daily or intermittently, teriparatide preferentially enhances osteoblastic function,and bone formation occurs. Continuous exposure to endogenous PTH may result in poor skeletal composition because of enhanced osteoclast-mediated bone resorption. After 18 months of treatment, lumbar BMD increased up to 12% in postmenopausal women. After 10 months of treatment, 53% of men had an increase of 5% or greater in spine BMD. The risk for developing new vertebral fractures was reduced by 65% after 21 months of treatment, and the number of nonvertebral fragility fractures was reduced by 53%.
Clinical Use
In 2002, the U.S. FDA approved teriparatide for the treatment of postmenopausal osteoporosis in patients who have a high risk of fracture as well as to increase bone mass in men with primary or hypogonadal osteoporosis who have a high risk of fracture. Teriparatide is recombinant human PTH 1-34, the biologically active portion of the endogenously produced preprohormone. Unlike the bisphosphonates, which are classified as bone restorative agents, teriparatide is the first approved bone-forming agent. Bone formation is possible because of the ability of this agent to increase the number of osteoblasts. Although teriparatide enhances the function of both osteoclasts and osteoblasts, the exposure incidence dictates its effect on the skeleton.
Side effects
Temporary increases in serum calcium levels occur following administration of teriparatide. As a result, this agent is contraindicated in patients who are predisposed to hypercalcemia. Some evidence suggests that these elevations in serum calcium levels may cause a patient who is taking digitalis to experience digitalis toxicity (39). Teriparatide should not be prescribed to patients with Paget's disease, children, young adults, women who are pregnant or nursing, and those patients who have received skeletal radiation therapy. Because of an increased incidence of osteosarcoma (malignant bone tumors) observed in rats, teriparatide also carries a black box warning
Dosage
Teriparatide acetate requires subcutaneous injection into the thigh or abdominal wall, and the recommended dose is 20 mcg once daily. If symptoms of orthostatic hypotension occur, it is administered while the patient is sitting or lying down. It is not recommended to use the drug for more than 2 years in the lifetime of the patient. Use teriparatide injection with caution in patients receiving digoxin. Transient hypercalcemia may predispose patients to digitalis toxicity.
References
[1] Jeeho Sim. “Development of Clinical Weekly-Dose Teriparatide Acetate Encapsulated Dissolving Microneedle Patch for Efficient Treatment of Osteoporosis.” Polymers (2022).
Teriparatide acetate Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Manus Aktteva | +91 (79) 6512-3395 | New Delhi, India | 581 | 34 | Inquiry |
| CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
| Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6773 | 58 | Inquiry |
| Sudarshan Pharma Industries Limited | 07942563481 | Mumbai, India | 3 | 58 | Inquiry |
| Sea Biological Co.,LTD | +86-13865152372 +86-13865152372 | China | 71 | 58 | Inquiry |
| Cellmano Biotech Limited | 0551-65326643 18156095617 | China | 999 | 58 | Inquiry |
| Hebei Xinsheng New Material Technology Co., LTD. | +86-16632316109 | China | 1090 | 58 | Inquiry |
| Zibo Hangyu Biotechnology Development Co., Ltd | +86-0533-2185556 +8617865335152 | China | 10978 | 58 | Inquiry |
| Hebei Weimiao Import and Export Trade Co., Ltd. | +undefined19948166995 | China | 73 | 58 | Inquiry |
| Shanghai Getian Industrial Co., LTD | +86-15373193816 +86-15373193816 | China | 269 | 58 | Inquiry |
Related articles
- The Pharmacokinetics and uses of Teriparatide acetate
- The anabolic drug teriparatide acetate has been introduced as a novel therapeutic agent for osteoporosis.
- Jan 2，2024
52232-67-4(Teriparatide acetate)Related Search:
1of4
chevron_right